High Blood Sugar News and Research

RSS

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announced today that the U.S. Food and Drug Administration approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2 2015.

26 Feb 2015

DPP-4 inhibitors effective against low blood sugar levels

DPP-4 inhibitors are a group of drugs used to treat type 2 diabetes that lower high blood sugar levels by stimulating insulin production in the body. Researchers at Lund University in Sweden have now discovered that DPP-4 inhibitors are also effective against low blood sugar levels.

23 Feb 2015

Scientists reveal genetic links to metabolic disorders

For at least 40 years, scientists who study how the body metabolizes sugar have accepted one point: there are four enzymes that kick-start the body's process of getting energy from food.

5 Feb 2015

Women’s risk factors for heart disease

Heart disease is often thought of as a health problem for men, but more and more women die of heart disease each year than men, and from any other disease including breast cancer.

4 Feb 2015

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV.

29 Dec 2014

Negative health effects of severe obesity

The negative health effects of severe obesity are very well known and have been thoroughly documented, yet obesity levels in the United States continue to remain stubbornly high. Many of these repercussions are life threatening and include heart attack, stroke, and a greatly increased chance of developing cancer.

27 Dec 2014

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

16 Dec 2014

New drug shows promise against treatment-resistant non-small cell lung cancer

A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial.

23 Nov 2014

Hospital bed positioning can affect outcomes of stroke patients

During the first 24 hours after a stroke, attention to detail --such as hospital bed positioning -- is critical to patient outcomes.

31 Oct 2014

Treating prediabetes patients could help prevent severe complications associated with diabetes

Doctors at three leading research institutions and the American Diabetes Association report that treating patients with prediabetes as if they had diabetes could help prevent or delay the most severe complications associated with this chronic disease, which affects about thirty million people in the United States.

25 Sep 2014

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

16 Sep 2014

Positive clinical data for first procedural therapy to treat type 2 diabetes from Fractyl

Fractyl Laboratories Inc. today announced positive clinical data for the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes.

4 Sep 2014

UT Southwestern researchers discover crucial link between high insulin levels and obesity pathways

UT Southwestern Medical Center researchers have identified a crucial link between high levels of insulin and pathways that lead to obesity, a finding that may have important implications when treating diabetes.

26 Aug 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.

11 Aug 2014

Tree nuts have positive impact on glycemic control in diabetes and on metabolic syndrome criteria

Two new meta-analyses involving tree nuts (almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios and walnuts) were recently published in the online publications, British Medical Journal Open (BMJ Open) and PLOS ONE.

1 Aug 2014

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

29 Jul 2014

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

29 Jul 2014

Researchers recommend low carbohydrate diet for Type 1 and Type 2 diabetes

A new study involving researchers from the University of Alabama at Birmingham and other institutions says patients with Type 1 and Type 2 diabetes should eat a diet low in carbohydrates.

25 Jul 2014

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.

24 Jul 2014

Labelling people as pre-diabetic is drastically premature measure with no medical value

Labelling people with moderately high blood sugar as pre-diabetic is a drastically premature measure with no medical value and huge financial and social costs, say researchers from UCL and the Mayo Clinic, Minnesota.

15 Jul 2014